EC
SRPT icon

Elequin Capital’s Sarepta Therapeutics SRPT Stock Holding History

Elequin Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54 Sell
3
-100
-97% -$1.89K ﹤0.01% 676
2026
Q1 		$2.24K Sell
103
-117
-53% -$2.27K ﹤0.01% 472
2025
Q4 		$4.73K Buy
+220
New +$4.64K ﹤0.01% 304
2025
Q1 		– Sell
-153
Closed -$18.6K – 617
2024
Q4 		$18.6K Buy
153
+25
+20% +$3.06K ﹤0.01% 270
2024
Q3 		$16K Buy
+128
New +$17.7K ﹤0.01% 196
2024
Q2 		– Sell
-198
Closed -$25.6K – 344
2024
Q1 		$25.6K Buy
+198
New +$24.3K ﹤0.01% 44
2023
Q3 		– Sell
-189
Closed -$21.6K – 597
2023
Q2 		$21.6K Buy
189
+178
+1,618% +$23K 0.01% 230
2023
Q1 		$1.52K Buy
+11
New +$1.43K ﹤0.01% 262
2022
Q3 		– Sell
-331
Closed -$25K – 664
2022
Q2 		$25K Buy
331
+22
+7% +$1.62K 0.01% 180
2022
Q1 		$24K Buy
+309
New +$23.7K ﹤0.01% 108

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Elequin Capital's SRPT Position: Q2 2026 in Review

Elequin Capital reduced its Sarepta Therapeutics (SRPT) stake by 97% in Q2 2026, selling an estimated $1.89K and leaving 3 shares worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #676.

Elequin Capital first reported a position in SRPT in Q1 2022 and has held it in 10 quarters since. The position peaked at $25.6K in Q1 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Elequin Capital held 3 shares of Sarepta Therapeutics worth $54 as of Q2 2026.
  • Elequin Capital sold 100 Sarepta Therapeutics shares in Q2 2026, an estimated $1.89K.
  • Sarepta Therapeutics made up ﹤0.01% of Elequin Capital's portfolio in Q2 2026, its #676 holding.
  • Elequin Capital first reported a position in Sarepta Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • Elequin Capital's Sarepta Therapeutics position peaked at $25.6K in Q1 2024.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.